The ‘new’ lust drug, aka ‘Barbie’ drug

PT-141 has been under development for some time by Palatin Technologies of New Jersey. But, as it sits on the cusp of phase 3, or late-stage, human trials, it’s getting renewed attention.

This drug – a nasal spray – could have big consequences for at least two local biotechs. ICOS Corp.’s erectile dysfunction drug, Cialis, could face trouble from new competition. Secondly, Nastech Pharmaceutical Co. was working on its own sexual dysfunction nasal spray, apomorphine, which was in phase 2 tests at last check.

Here’s Palatin’s own description of the drug: http://www.palatin.com/products/pt141/overview.asp

Here’s a story about it: http://www.montereyherald.com/mld/montereyherald/living/health/13223608.htm

Here’s a rather long New York Magazine story about PT-141 and the physical and potential psychological and social ramifications of a drug that tricks your brain into being in the mood: http://www.newyorkmetro.com/lifestyle/sex/annual/2005/15061/index.html

Finally, a story about why PT-141 and related drugs are being called “Barbie drugs”: http://abclocal.go.com/ktrk/story?section=special_coverage&id=3435222